Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Recipient : AeroRx
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration sets forth the framework by which both companies will work together to develop a new nebulized LABA/LAMA combination formulation for the treatment of chronic obstructive pulmonary disease (COPD).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 02, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Recipient : AeroRx
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Human Plasma-Derived Polyvalent Immunoglobulin G
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Recipient : CSL Behring
Deal Size : Undisclosed
Deal Type : Collaboration
HCmed Reaches Milestone in Immunoglobin Combination Product Development with CSL Behring
Details : CSL Behring partnered with HCmed to develop a combination product consisting of a plasma-derived immunoglobulin formulation (CSL787) administered via a customized version of the AdheResp nebulizer, HCmed's breath-actuated mesh nebulizer.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
October 24, 2021
Lead Product(s) : Human Plasma-Derived Polyvalent Immunoglobulin G
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Recipient : CSL Behring
Deal Size : Undisclosed
Deal Type : Collaboration